DelveInsight’s, “Esophageal Cancer Pipeline Insight, 2023” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Esophageal Cancer pipeline landscape. It covers the Esophageal Cancer pipeline drug profiles, including Esophageal Cancer clinical trials and nonclinical stage products. It also covers the Esophageal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Esophageal Cancer Emerging drugs, the Esophageal Cancer pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Esophageal Cancer pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Esophageal Cancer Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Esophageal Cancer clinical trials studies, Esophageal Cancer NDA approvals (if any), and product development activities comprising the technology, Esophageal Cancer collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Esophageal Cancer Pipeline Report

 

• Over 80+ Esophageal Cancer companies are evaluating 80+ Esophageal Cancer pipeline therapies in various stages of development, and their anticipated acceptance in the Esophageal Cancer market would significantly increase market revenue.

 

• The leading Esophageal Cancer Companies include BeiGene, AstraZeneca, CSPC ZhongQi Pharmaceutical Technology, Amgen, Jiangsu Hengrui Medicine, Oncolys Biopharma, Pfizer, Novartis, Luye Pharma, Eli Lilly and Company, ImmunoFrontier, Inc, Adaptimmune, Innovent Biologics (Suzhou) Co. Ltd., Genentech, Janssen Pharmaceuticals, Merck KGaA, Shenzhen Hornetcorn Biotechnology, Apexigen, Inc., Highlight Therapeutics, EMD Serono, HaiHe Biopharma, Shenzhen BinDeBio Ltd., Lumicell, Jacobio Pharmaceuticals Co., Ltd., TESARO, Ascentage Pharma Group Inc., Guangdong Xiangxue Precision Medical Technology, CytomX Therapeutics, Shionogi, Guangdong Zhongsheng Pharmaceutical Co., Ltd., VM Oncology, LLC, Dragonfly Therapeutics, TG Therapeutics, AVEO Pharmaceuticals, OncoTherapy Science, Sorrento Therapeutics, Incyte Corporation, Roche, Henlix Biotech, Athenex, Biostage, Celldex Therapeutics, Kymab Limited, NGM Biopharmaceuticals, Seagen Inc., and others.
• Promising Esophageal Cancer pipeline therapies includes Tislelizumab, Durvalumab, Mitoxantrone liposomal, Panitumumab, SHR-1210, OBP-301, Apatinib, Sunitinib malate, RAD001, Irinotecan, Ramucirumab, IMF-001, Autologous genetically modified ADP-A2M4CD8 cells, Sintilimab, Atezolizumab, Erdafitinib, M6620, DC-CIK, APX005M, BO-112, M1231, Ramucirumab, CYH33, PCA062, CAR-T/TCR-T cells, LUM015, JAB-3068, Niraparib, APG-2449, TAEST16001, CX-2029, S-488210, ZSP1241, VMD-928 300, DF6002, TGR-1202, AV 203, S-588410, Socazolimab, AMG 337, Retifanlimab, RO 7092284, Serplulimab, Cellspan Esophageal implant, CDX-1140, KY1044, NGM120, SGN-B6A, NP-G2-044, ADCT-301, AB308, Epacadostat, SCT-I10A, Larotinib, KN046, Sugemalimab, and others.

 

• The Esophageal Cancer companies and academics are working to assess challenges and seek opportunities that could influence Esophageal Cancer R&D. The Esophageal Cancer pipeline therapies under development are focused on novel approaches to treat/improve Esophageal Cancer.

 

Request a sample and discover the recent breakthroughs happening in the Esophageal Cancer Pipeline landscape @ Esophageal Cancer Pipeline Outlook Report

 

Esophageal Cancer Overview

Esophageal cancer develops in the esophagus, which is the tube that connects throat to the stomach. Tumors arise in the mucosa, which is the inner lining of the esophagus. There are two types of esophageal cancer, each with different risk factors: Adenocarcinoma -Cancers that start in gland cells at the bottom of the esophagus are called adenocarcinomas. This type of cancer is the most common esophageal cancer. It usually occurs closer to the stomach. Chronic acid reflux, gastroesophageal reflux disease (GERD), Barrett’s esophagus and chronic heartburn can increase the risk of developing adenocarcinoma esophageal cancer.

 

Recent Developmental Activities in the Esophageal Cancer Treatment Landscape

 

• In September 2020, BeiGene announced that the U.S. Food and Drug Administration (FDA) accepted to review a Biologics License Application (BLA) for their anti-PD-1 antibody tislelizumab to treat patients with unresectable recurrent locally advanced or metastatic Esophageal Squamous Cell Carcinoma (ESCC). July 12, 2022, is the Prescription Drug User Fee Act (PDUFA) target action date.

 

• CX-2029, co-developed by CytomX and AbbVie is a PDC directed against CD71, the transferrin receptor which is highly expressed on a number of solid and hematologic tumors, including diffuse large B-cell lymphoma and also Esophageal Cancer.

 

• Telomelysin (OBP-301) is a gene-modified oncolytic adenovirus that selectively replicates in cancer cells by introducing human telomerase reverse transcriptase (hTERT) promoter. A Japanese pharmaceutical company Chugai Pharmaceutical is conducting phase 2 study, based on the exclusive license agreement for Telomelysin concluded between Chugai and Oncolys on 8 April, 2019.

 

• Zymeworks’ lead product candidate, zanidatamab, is a HER2-targeted bispecific antibody developed using Zymeworks proprietary Azymetric™ platform. Zanidatamab has been granted Fast Track designation for first-line gastroesophageal adenocarcinoma in combination with standard of care chemotherapy.

 

• In May 2020, Rafael Pharmaceuticals Enters into Research Collaboration with Roswell Park Comprehensive Cancer Center to Evaluate the Effects of CPI-613® (Devimistat) on Esophageal Cancer.

 

• Nanobiotix is evaluating NBTXR3 in Phase I clinical trial. The trial was conducted as a part of an ongoing clinical collaboration at The University of Texas MD Anderson Cancer Center (MD Anderson). 

 

For further information, refer to the detailed Esophageal Cancer Drugs Launch, Esophageal Cancer Developmental Activities, and Esophageal Cancer News, click here for Esophageal Cancer Ongoing Clinical Trial Analysis

 

Esophageal Cancer Emerging Drugs Profile

 

• AN-0025: Adlai Nortye

AN0025 is a clinical stage, potential first-in-class EP4 antagonist designed to modulate tumor microenvironment. It blocks the PGE2-EP4 signaling pathway to inhibit PGE2-mediated immunosuppression in the tumor microenvironment. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Esophageal Cancer.

 

• Tucatinib: Seagen

Tucatinib (TUKYSA®) is an oral medicine that is a tyrosine kinase inhibitor of the HER2 protein, a protein that contributes to cancer cell growth.HER2 is overexpressed in multiple cancers, including breast, colorectal, and gastric cancers. In preclinical in vitro studies, TUKYSA inhibited phosphorylation of HER2 and HER3, resulting in inhibition of downstream MAPK and AKT signaling and cell growth (proliferation), and showed anti-tumor activity in HER2-expressing tumor cells. In preclinical and clinical studies, TUKYSA inhibited the growth of HER2-expressing tumors. The combination of TUKYSA and the anti-HER2 antibody trastuzumab has also been shown to increase anti-tumor activity in vitro and in vivo compared to either medicine alone. Currently, the drug is in Phase II/III stage of Clinical trial evaluation for the treatment of Esophageal Cancer.

 

• APX 005M: Apexigen

APX005M is a novel, humanized monoclonal antibody that stimulates the anti-tumor immune response. APX005M targets CD40, a co-stimulatory receptor that is essential for activating both innate and adaptive immune systems. Binding of APX005M to CD40 on antigen presenting cells (i.e., dendritic cells, monocytes and B-cells) initiates a multi-faceted immune response bringing multiple components of the immune system (e.g., T cells, macrophages) to work in concert against cancer. APX005M is currently in Phase 2 clinical development for the treatment of cancers such as pancreatic cancer, esophageal and gastroesophageal junction cancers, melanoma, non-small cell lung cancer, rectal cancer and sarcoma in various combinations with immunotherapy, chemotherapy, radiation therapy or a cancer vaccine.

 

Esophageal Cancer Pipeline Segmentation

 

Phases

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

 

Molecule Type

• Oligonucleotide
• Peptide
• Small molecule

 

Esophageal Cancer Pipeline Therapeutics Assessment

There are approx. 80+ key companies which are developing the therapies for Esophageal Cancer. The companies which have their Esophageal Cancer drug candidates in the most advanced stage, i.e. phase II/III include, Seagen.

 

Find out more about the Esophageal Cancer Pipeline Segmentation, Therapeutics Assessment, and Esophageal Cancer Emerging Drugs @ Esophageal Cancer Treatment Landscape

 

Scope of the Esophageal Cancer Pipeline Report

 

• Coverage- Global

 

• Esophageal Cancer Companies- BeiGene, AstraZeneca, CSPC ZhongQi Pharmaceutical Technology, Amgen, Jiangsu Hengrui Medicine, Oncolys Biopharma, Pfizer, Novartis, Luye Pharma, Eli Lilly and Company, ImmunoFrontier, Inc, Adaptimmune, Innovent Biologics (Suzhou) Co. Ltd., Genentech, Janssen Pharmaceuticals, Merck KGaA, Shenzhen Hornetcorn Biotechnology, Apexigen, Inc., Highlight Therapeutics, EMD Serono, HaiHe Biopharma, Shenzhen BinDeBio Ltd., Lumicell, Jacobio Pharmaceuticals Co., Ltd., TESARO, Ascentage Pharma Group Inc., Guangdong Xiangxue Precision Medical Technology, CytomX Therapeutics, Shionogi, Guangdong Zhongsheng Pharmaceutical Co., Ltd., VM Oncology, LLC, Dragonfly Therapeutics, TG Therapeutics, AVEO Pharmaceuticals, OncoTherapy Science, Sorrento Therapeutics, Incyte Corporation, Roche, Henlix Biotech, Athenex, Biostage, Celldex Therapeutics, Kymab Limited, NGM Biopharmaceuticals, Seagen Inc., and others.

 

• Esophageal Cancer Pipeline Therapies- Tislelizumab, Durvalumab, Mitoxantrone liposomal, Panitumumab, SHR-1210, OBP-301, Apatinib, Sunitinib malate, RAD001, Irinotecan, Ramucirumab, IMF-001, Autologous genetically modified ADP-A2M4CD8 cells, Sintilimab, Atezolizumab, Erdafitinib, M6620, DC-CIK, APX005M, BO-112, M1231, Ramucirumab, CYH33, PCA062, CAR-T/TCR-T cells, LUM015, JAB-3068, Niraparib, APG-2449, TAEST16001, CX-2029, S-488210, ZSP1241, VMD-928 300, DF6002, TGR-1202, AV 203, S-588410, Socazolimab, AMG 337, Retifanlimab, RO 7092284, Serplulimab, Cellspan Esophageal implant, CDX-1140, KY1044, NGM120, SGN-B6A, NP-G2-044, ADCT-301, AB308, Epacadostat, SCT-I10A, Larotinib, KN046, Sugemalimab, and others.

 

• Esophageal Cancer Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration 

 

Dive deep into rich insights for drugs for Esophageal Cancer Pipeline Companies and Therapies, click here @ Esophageal Cancer Unmet Needs and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Esophageal Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Esophageal Cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Pre-Registration)
8. Drug Name : Company Name
9. Drug profiles in the detailed report…..
10. Last Stage Products (Phase  II/III)
11. Tucatinib: Seagen
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. APX 005M: Apexigen
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name : Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Esophageal Cancer Key Companies
21. Esophageal Cancer Key Products
22. Esophageal Cancer – Unmet Needs
23. Esophageal Cancer – Market Drivers and Barriers
24. Esophageal Cancer – Future Perspectives and Conclusion
25. Esophageal Cancer Analyst Views
26. Esophageal Cancer Key Companies
27. Appendix

 

Got Queries? Find out the related information on Esophageal Cancer Mergers and acquisitions, Esophageal Cancer Licensing Activities @ Esophageal Cancer Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/